Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity

已完结 10 由 honey 发布于 2026/4/1 23:55:03

DOI:10.1016/j.bcp.2024.116542
作者：Xiaoyi Zhang , Yachuan Tao , Zhongli Xu , Biao Jiang , Xiaobao Yang , Taomin Huang , Wenfu Tan
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：The overexpression of BCL-xL is closely associated with poor prognosis in hepatocellular carcinoma (HCC). While the strategy of combination of BCL-xL and MCL-1 for treating solid tumors has

应助信息

13小时前

cuifang

3c89f7262de311f1912734735aa3bc31.pdf 已采纳

13小时前

Book学术机器人

2026/4/1 23:55:04 未找到该文献，机器人已退出，请等待人工下载

2026/4/1 23:55:03 Book学术AI机器人收到请求，开始寻找文献

2026/4/1 23:55:03 已向机器人发送请求

13小时前

honey 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网基于动态磁聚焦的CT球管飞焦点研究